Investing in a new and rapidly expanding industry is a great way to bolster your portfolio, and it’s also quite fun. Of course, we can’t always know in advance which areas are going to be big, so it’s hard to know where to invest before the crowd shows up. That’s roughly what I tell myself when I’m trying to come to terms with missing out on investing in the cannabis industry’s boom before valuations skyrocketed over the last few years, at least.
Luckily, there’s another new industry that’s gaining traction right now, and sharp investors are already starting to take note. Psychedelic medicines are in their early stages of testing and adoption, but once they make it to the mainstream in the pharmaceutical market, early shareholders could end up rich.
Psychedelics aren’t on the fringe anymore
Investors are right to be skeptical of the concept of psychedelic medicines. After all, the only reason that most people know anything about psychedelic drugs is that they are illegal in the U.S. Medical research into psychedelics is tightly restricted, not to mention socially stigmatized and financially risky. But these longstanding trends are shifting rapidly.
These shifts start with the advent of highly promising scientific research. Recent studies have shown that very ill cancer patients experience less existential distress, depression, and anxiety for as long as six months after getting psilocybin (“magic…
Original Author Link click here to read complete story..
Investing in a new and rapidly expanding industry is a great way to bolster your portfolio, and it’s also quite fun. Of course, we can’t always know in advance which areas are going to be big, so it’s hard to know where to invest before the crowd shows up. That’s roughly what I tell myself when I’m trying to come to terms with missing out on investing in the cannabis industry’s boom before valuations skyrocketed over the last few years, at least.
Luckily, there’s another new industry that’s gaining traction right now, and sharp investors are already starting to take note. Psychedelic medicines are in their early stages of testing and adoption, but once they make it to the mainstream in the pharmaceutical market, early shareholders could end up rich.
Psychedelics aren’t on the fringe anymore
Investors are right to be skeptical of the concept of psychedelic medicines. After all, the only reason that most people know anything about psychedelic drugs is that they are illegal in the U.S. Medical research into psychedelics is tightly restricted, not to mention socially stigmatized and financially risky. But these longstanding trends are shifting rapidly.
These shifts start with the advent of highly promising scientific research. Recent studies have shown that very ill cancer patients experience less existential distress, depression, and anxiety for as long as six months after getting psilocybin (“magic…